Avacopan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 320 publications
UK regulator plans to withdraw controversial vasculitis drug Tavneos over unreliable data.
Journal: BMJ (Clinical research ed.)
Published: September 02, 2026
Retraction of: Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Journal: Modern rheumatology
Published: August 25, 2026
Lessons in neuroimmunology from the retracted avacopan trial paper.
Journal: Multiple sclerosis and related disorders
Published: August 08, 2026
Notice of Retraction from ACP Journal Club: In ANCA-associated vasculitis, avacopan was superior to prednisone taper for sustained remission.
Journal: Annals of internal medicine
Published: August 03, 2026
Vanishing Bile Duct Syndrome During Avacopan Therapy.
Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
Published: July 17, 2026
Hepatotoxicity of Avacopan: Real-World Incidence and Confirmed Cases of Severe Drug-Induced Liver Injury in a US National Rheumatology Registry.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: July 10, 2026
Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609.
Journal: The New England journal of medicine
Published: June 30, 2026
Update on therapeutic approaches in ANCA-associated vasculitis.
Journal: EULAR rheumatology open
Published: June 29, 2026
Last Updated: 09/26/2026